Biogen Inc.
(NASDAQ : BIIB)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Loading BIIB News...
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
0.28%72.671.2%$696.83m
CELGCelgene Corporation
-4.70%111.871.3%$645.43m
AMGNAmgen Inc.
-3.40%140.171.0%$605.61m
BIIBBiogen Inc.
-2.33%284.381.2%$526.97m
REGNRegeneron Pharmaceuticals, Inc.
-2.85%358.453.6%$382.78m
ALXNAlexion Pharmaceuticals, Inc.
0.73%125.071.9%$363.71m
ILMNIllumina, Inc.
-3.51%121.963.0%$177.14m
VRTXVertex Pharmaceuticals Incorporated
-3.11%75.692.9%$164.83m
INCYIncyte Corporation
-3.79%103.152.4%$161.54m
TSROTESARO, Inc.
-2.60%136.2417.1%$156.34m
IONSIonis Pharmaceuticals, Inc.
-3.52%45.7810.0%$147.58m
EXELExelixis, Inc.
-9.21%16.576.4%$116.16m
BMRNBioMarin Pharmaceutical Inc.
-1.84%81.474.5%$114.14m
BLUEBluebird Bio, Inc.
-9.44%71.5023.3%$112.20m
AAgilent Technologies, Inc.
-0.07%44.811.6%$111.54m

Company Profile

Biogen, Inc. is a global biotechnology company, which focuses on discovering, developing, manufacturing and delivering therapies for neurological, autoimmune and hematologic disorders. Its products include AVONEX, PLEGRIDY, TECFIDERA, TYSABRI, and FAMPYRA for multiple sclerosis, ALPROLIX for hemophilia B and ELOCTATE for hemophilia A. The company also collaborates on the development and commercialization of RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and other conditions and share profits and losses for GAZYVA which is approved for the treatment of chronic lymphocytic leukemia. Biogen was founded by Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.